Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDN-1
- Development stage
- Unknown
- Lead developer
- Gordagen Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Sublingual, Oral
01
Overview
GDN-1 is a proprietary sublingual formulation of tocotrienols, specifically alpha-tocotrienol, developed by Gordagen Pharmaceuticals. The drug utilizes a specialized delivery technology designed to enhance the bioavailability of tocotrienols by bypassing first-pass metabolism through sublingual absorption. Tocotrienols are members of the Vitamin E family known for their potent antioxidant and anti-inflammatory properties. GDN-1 is primarily being developed for the management of exercise-induced muscle soreness and recovery, with potential applications in cardiovascular health and metabolic disorders. It has been evaluated in Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics compared to standard oral delivery.
- Other names
- alpha-tocotrienol formulationsublingual tocotrienol
02
Targets
NF-κBHMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on GDN-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GDN-1.